Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study
European Journal of Neurology · 2026-05 · 33 (5)
DOI: 10.1111/ene.70625 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Neurology, online erschienen am 16.05.2026. Verfasst von Maiju Savolainen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neurocenter, Helsinki University Hospital, and Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Rituximab, Multiple Sclerosis, Relapsing-Remitting, Antibodies, Monoclonal, Humanized, Immunologic Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Helsinki University Hospital, Turku University Hospital, Turun Yliopistollinen Keskussairaala.
Abstract (Originalsprache)
Background
B‐cell–depleting anti‐CD20 therapies are among the most effective disease‐modifying treatments for relapsing–remitting multiple sclerosis (RRMS). Rituximab (RTX) is widely used off‐label, while ocrelizumab (OCR) is approved for RRMS; yet comparative real‐world evidence between the two remains limited.
Methods
We conducted a retrospective registry‐based cohort study using the Finnish MS Registry, including adult RRMS patients treated with RTX or OCR between 2018 and 2024 at two university hospitals. Propensity score matching (1:1) was applied to balance baseline characteristics. Primary outcomes were annualized relapse rate (ARR) during follow‐up and relapse‐free survival. Secondary outcomes included MRI activity, disability progression, adverse events, and longitudinal plasma immunoglobulin G (IgG) levels.
Results
Of 636 screened patients, 191 met inclusion criteria and 112 patients (56 RTX, 56 OCR) were included after matching. Median follow‐up was 3.1 years for RTX and 2.6 years for OCR. ARR was low and similar in both groups (mean 0.03), and relapse‐free survival did not differ (log‐rank p = 0.95; HR 0.95, 95% CI 0.21–4.33). MRI activity remained largely stable, with no significant differences in T2 lesion changes. Adverse events were infrequent and mild. IgG declined modestly in both groups (mean−13%), with values below the reference range in 4.5% of patients and no association with infections. No disease reactivation was observed among patients switching from OCR to RTX.
Conclusions
In this population‐based Finnish real‐world study, RTX and OCR demonstrated comparable effectiveness and safety in RRMS, supporting RTX as a rational alternative to OCR in routine clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurocenter, Helsinki University Hospital, and Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland.
- Neurocenter, Turku University Hospital and Division of Clinical Neurosciences, University of Turku, Turku, Finland.
- StellarQ Ltd, Turku, Finland.
- Aastat Ltd, Turku, Finland.
ORCID-Profile: Maiju Savolainen
Förderung
- Helsinki University Hospital
- Turku University Hospital
- Turun Yliopistollinen Keskussairaala
Zitieren
APA
Savolainen, M., Soilu-Hänninen, M., Nurmi, H., Viitala, M., Tienari, P., Atula, S., & Laakso, S. M. (2026). Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study. European Journal of Neurology, 33(5). https://doi.org/10.1111/ene.70625
Vancouver
Savolainen M, Soilu-Hänninen M, Nurmi H, Viitala M, Tienari P, Atula S, et al. Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study. European Journal of Neurology. 2026;33(5). doi:10.1111/ene.70625
BibTeX
@article{Savolainen2026,
author = {Savolainen, Maiju and Soilu-Hänninen, Merja and Nurmi, Henriikka and Viitala, Matias and Tienari, Pentti and Atula, Sari and Laakso, Sini M},
title = {Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/ene.70625}
}
EUVIMED